Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.43 |
| ▸ | TSHR | P16473 | 1/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.39 |
| ▸ | MAPT | P10636 | 2/20 | 0.39 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.39 |
| ▸ | HTT | P42858 | 1/20 | 0.39 |
| ▸ | CASP3 | P42574 | 10/20 | 0.36 |
| ▸ | CASP6 | P55212 | 9/20 | 0.35 |
| ▸ | CASP8 | Q14790 | 9/20 | 0.35 |
| ▸ | CASP7 | P55210 | 1/20 | 0.35 |
| ▸ | POLB | P06746 | 1/20 | 0.34 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.34 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.34 |
| ▸ | PKM | P14618 | 1/20 | 0.32 |
| ▸ | CTSV | O60911 | 1/20 | 0.32 |
| ▸ | CTSL | P07711 | 1/20 | 0.32 |
| ▸ | CTSB | P07858 | 1/20 | 0.32 |
| ▸ | CTSH | P09668 | 1/20 | 0.32 |
| ▸ | CTSS | P25774 | 1/20 | 0.32 |
| ▸ | CTSK | P43235 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22307837 | 0.85 | KDM4E (0.55) | ALDH1A1MAPTKDM4EHTTCASP3 | |
| SCHEMBL22307831 | 0.77 | CTSH (0.45) | ALDH1A1CASP3CASP6CASP8CTSH | |
| SCHEMBL17229449 | 0.76 | SMN1; SMN2 (0.41) | SMN1; SMN2TSHRALDH1A1MAPTKDM4E | |
| SCHEMBL8827471 | 0.76 | TSHR (0.47) | SMN1; SMN2TSHRALDH1A1MAPTKDM4E | |
| SCHEMBL7313557 | 0.75 | TSHR (0.50) | SMN1; SMN2TSHRALDH1A1MAPTKDM4E | |
| SCHEMBL503651 | 0.73 | SMN1; SMN2 (0.70) | SMN1; SMN2TSHRALDH1A1MAPTPOLB | |
| SCHEMBL3026303 | 0.71 | TSHR (0.47) | SMN1; SMN2TSHRALDH1A1MAPTKDM4E | |
| SCHEMBL4920850 | 0.71 | TSHR (0.47) | SMN1; SMN2TSHRALDH1A1MAPTKDM4E | |
| SCHEMBL12636212 | 0.71 | TSHR (0.47) | SMN1; SMN2TSHRALDH1A1MAPTKDM4E | |
| SCHEMBL25985226 | 0.71 | KDM4E (0.52) | ALDH1A1MAPTKDM4EHTTCASP3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10844077-B2 | Thiazolyl-containing compounds for treating proliferative diseases | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2020-11-24 | — | — | US | disclosed |
| US-20200165267-A1 | THIAZOLYL-CONTAINING COMPOUNDS FOR TREATING PROLIFERATIVE DISEASES | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2020-05-28 | — | — | US | disclosed |
| US-10464949-B2 | Thiazolyl-containing compounds for treating proliferative diseases | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2019-11-05 | — | — | US | disclosed |
| US-20190119301-A1 | THIAZOLYL-CONTAINING COMPOUNDS FOR TREATING PROLIFERATIVE DISEASES | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2019-04-25 | — | — | US | disclosed |
| US-9879028-B2 | Compounds that modulate EGFR activity and methods for treating or preventing conditions therewith | Gatekeeper Pharmaceuticals, Inc. (US) | 2018-01-30 | — | — | US | disclosed |
| US-9879028-B2 | Compounds that modulate EGFR activity and methods for treating or preventing conditions therewith | Gatekeeper Pharmaceuticals, Inc. (US) | 2018-01-30 | — | — | US | disclosed |
| US-20170233411-A1 | THIAZOLYL-CONTAINING COMPOUNDS FOR TREATING PROLIFERATIVE DISEASES | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2017-08-17 | — | — | US | disclosed |
| US-20170233411-A1 | THIAZOLYL-CONTAINING COMPOUNDS FOR TREATING PROLIFERATIVE DISEASES | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2017-08-17 | — | — | US | disclosed |
| US-20160137610-A1 | Compounds that Modulate EGFR Activity and Methods for Treating or Preventing Conditions Therewith | Gatekeeper Pharmaceuticals, Inc. | 2016-05-19 | — | — | US | disclosed |
| US-20140011810-A1 | Compounds that Modulate EGFR Activity and Methods for Treating or Preventing Conditions Therewith | Gatekeeper Pharmaceuticals, Inc. (US) | 2014-01-09 | — | — | US | disclosed |
| US-20130137709-A1 | Compounds that modulate EGFR activity and methods for treating or preventing conditions therewith | Gatekeeper Pharmaceuticals, Inc. | 2013-05-30 | — | — | US | disclosed |
| US-20110207736-A1 | COMPOUNDS THAT MODULATE EGFR ACTIVITY AND METHODS FOR TREATING OR PREVENTING CONDITIONS THEREWITH | Gatekeeper Pharmaceuticals, Inc. | 2011-08-25 | — | — | US | disclosed |
| US-7767818-B2 | Hepatitis C inhibitor dipeptide analogs | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2010-08-03 | — | — | US | disclosed |
| US-20090156822-A1 | Hepatitis C Inhibitor Dipeptide Analogs | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2009-06-18 | — | — | US | disclosed |
| US-7511157-B2 | racemic mixtures, stereoisomers or optical isomers, useful as protease inhibitors; viricides | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2009-03-31 | — | — | US | disclosed |
| US-5360819-A | Nonradioactive labels which provide a ketone signal, vapor phase analysis | NORTHEASTERN UNIVERSITY (US) | 1994-11-01 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (10 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160137610-A1 | Compounds that Modulate EGFR Activity and Methods for Treating or Preventing Conditions Therewith | EGFR, ERBB2, BRCA1 | SMN1; SMN2 1829/4885TSHR 1739/4885ALDH1A1 2351/4885 |
| US-20090156822-A1 | Hepatitis C Inhibitor Dipeptide Analogs | DPP3, CTSC, ANPEP | SMN1; SMN2 4344/4885TSHR 2730/4885ALDH1A1 1136/4885 |
| US-20200165267-A1 | THIAZOLYL-CONTAINING COMPOUNDS FOR TREATING PROLIFERATIVE DISEASES | BTK, BCL9L, MCL1 | SMN1; SMN2 4298/4885TSHR 1818/4885ALDH1A1 3854/4885 |
| US-20130137709-A1 | Compounds that modulate EGFR activity and methods for treating or preventing conditions therewith | EGFR, ERBB2, BRCA1 | SMN1; SMN2 1829/4885TSHR 1739/4885ALDH1A1 2351/4885 |
| US-20170233411-A1 | THIAZOLYL-CONTAINING COMPOUNDS FOR TREATING PROLIFERATIVE DISEASES | BTK, BCL9L, BCL9 | SMN1; SMN2 4131/4885TSHR 2001/4885ALDH1A1 3889/4885 |
| US-20190119301-A1 | THIAZOLYL-CONTAINING COMPOUNDS FOR TREATING PROLIFERATIVE DISEASES | BTK, BCL9L, BCL9 | SMN1; SMN2 4131/4885TSHR 2001/4885ALDH1A1 3889/4885 |
| US-10844077-B2 | Thiazolyl-containing compounds for treating proliferative diseases | BTK, BCL9L, MCL1 | SMN1; SMN2 4298/4885TSHR 1818/4885ALDH1A1 3854/4885 |
| US-10464949-B2 | Thiazolyl-containing compounds for treating proliferative diseases | BTK, BCL9L, BCL9 | SMN1; SMN2 4131/4885TSHR 2001/4885ALDH1A1 3889/4885 |
| US-20110207736-A1 | COMPOUNDS THAT MODULATE EGFR ACTIVITY AND METHODS FOR TREATING OR PREVENTING CONDITIONS THEREWITH | EGFR, ERBB2, BRCA1 | SMN1; SMN2 1829/4885TSHR 1739/4885ALDH1A1 2351/4885 |
| US-20140011810-A1 | Compounds that Modulate EGFR Activity and Methods for Treating or Preventing Conditions Therewith | EGFR, ERBB2, BRCA1 | SMN1; SMN2 1829/4885TSHR 1739/4885ALDH1A1 2351/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.